Peyronie’s disease: A “triple oxygenant therapy”

  • Francesco Ciociola | ciociolafrancesco@libero.it U.O.C. Urologia 2 - Andrologia e Riproduzione Assistita, Azienda Ospedaliera San Paolo - Polo Universitario, Milano, Italy.
  • Giovanni Maria Colpi U.O.C. Urologia 2 - Andrologia e Riproduzione Assistita, Azienda Ospedaliera San Paolo - Polo Universitario, Milano, Italy.

Abstract

Objectives: To evaluate the effects of upregulators of nitric oxide in one patient with Peyronie’s disease, after non significant improvement following intracavernosal verapamil. Methods: A 20-years-old Caucasian male presented with penile induration in flaccid state, persistent during erection and associated with mild pain at third middle of penis. After treatment with intracavernosal verapamil for 4 months with relief of penile discomfort, followed by counseling on the use of penile extender for at least 6 hours per day, he was prescribed pentoxifylline associated with tadalafil plus levo-arginine, propionil-carnitine and Vitamin B3. Results: After almost 2 years, the septal thickness was reduced at ultrasound evaluation after this “triple oxygenant therapy”. Conclusion: NO-iNOS biology in Peyronie patients is the very protagonist in modulating penile fibrosis through up-regulation of NO-cGMP pathway that influences penile health by preventing and reversing fibrosis in the tunical albuginea.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2013-04-19
Info
Issue
Section
Case Reports - Andrology
Keywords:
Peyronie's disease, Pentoxifylline, Penile fibrosis, Phosphodiesterase inhibitors, Tadalafil, L-arginine
Statistics
  • Abstract views: 2122

  • PDF: 3229
How to Cite
Ciociola, F., & Colpi, G. M. (2013). Peyronie’s disease: A “triple oxygenant therapy”. Archivio Italiano Di Urologia E Andrologia, 85(1), 36-40. https://doi.org/10.4081/aiua.2013.1.36